Eli Lilly and Company - AI Stock Analysis

Analysis generated January 9, 2026

Eli Lilly and Company is a global pharmaceutical powerhouse headquartered in Indianapolis, Indiana. Established in 1876, it has over a century of experience in the healthcare sector, focusing primarily on innovation and development in therapeutics. The company's primary products include treatments for diabetes, oncology, immunology, neuroscience, and more. Eli Lilly is renowned for advancing medicine through rigorous research and a commitment to improving patient outcomes.

Fundamental Analysis

Revenue for the last quarter was $17.6 billion, marking a substantial increase of 13.13% from the previous quarter. This uptick is indicative of a strong growth trajectory. When compared to the same quarter last year, revenue surged by an impressive 53.87%, further underscoring a positive year-over-year growth trend.

However, the net income for the last quarter was $5.58 billion, which dipped by 1.38% from the previous quarter. Despite this slight decrease, net income showed a remarkable year-over-year growth of 475.34%. This juxtaposition highlights both short-term concerns and long-term profitability.

EBITDA for the quarter stood at $7.88 billion, a 5.04% increase from the prior quarter and a staggering 250.64% rise from the same quarter last year. These numbers signify robust operational efficiency and profitability.

The current Price-to-Earnings (PE) ratio is 54.34, which seems relatively high, suggesting potential overvaluation. Investors need to be cautious, as a high PE ratio can often signal bearish outlooks.

Additionally, a recent trend of company insiders selling their stock could be perceived negatively, fueling concerns about the stock's future performance.

Technical Analysis

Today’s stock price is $1,101.71, climbing by 12.17% over the past month, which indicates a favorable short-term trend. Compared to a year ago, the stock has risen by 38.75%, showcasing a strong long-term bullish trend.

Furthermore, the current Simple Moving Average (SMA10) is $1,079.10, up from the previous SMA10 of $1,076.90, reinforcing the potential for continued upward price movement.

The Relative Strength Index (RSI) is 45.5, which falls into the neutral range, suggesting that the stock is neither oversold nor overbought at this stage.

Alternative Data Analysis

Job postings and employee sentiment data reveal stability at Eli Lilly and Company. Maintaining 856 open positions over the past few months indicates organizational stability. Additionally, 83% of employees have a positive outlook on the company’s future, highlighting a favorable internal business atmosphere.

In terms of customer acquisition, the company has seen an 18% increase in webpage visitors over the last couple of months, totaling an estimated 8.1 million visitors. This uptick is a bullish indicator implying potential growth in customer base and engagement.

Customer engagement data showcases a 15% increase in Instagram followers, now totaling 60,000, suggesting growing interest and engagement from the public. Conversely, a slight 1% decline in Twitter followers, now at 140,000, may indicate a minor dip in interest.

The AltIndex AI score for Eli Lilly and Company is 60, suggesting a 'hold' signal based on a combination of fundamental, technical, and alternative data analysis.

Conclusion and Recommendation

In summary, Eli Lilly and Company shows strong revenue, net income, and EBITDA growth on a year-over-year basis, although the PE ratio and recent insider sales might raise concerns. Technical indicators point to a bullish trend, which is promising. Alternative data reflects a stable internal environment and positive customer engagement metrics. Overall, Eli Lilly and Company appears to be a stable investment with a growth potential. Given the data, a 'hold' recommendation is advised. Investors should monitor the stock closely for any changes in fundamentals or market sentiment.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.